Treatment of chronic kidney disease | Zendy

Jeffrey M. Turner | Zendy; Carolyn Bauer | Zendy; Matthew K. Abramowitz | Zendy; Michal L. Melamed | Zendy; Thomas H. Hostetter | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of chronic kidney disease

Author(s) -

Jeffrey M. Turner,

Carolyn Bauer,

Matthew K. Abramowitz,

Michal L. Melamed,

Thomas H. Hostetter

Publication year - 2011

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1038/ki.2011.380

Subject(s) - medicine , kidney disease , hyperphosphatemia , glycemic , glycation , end stage renal disease , diabetes mellitus , disease , metabolic acidosis , advanced glycation end product , intensive care medicine , endocrinology

Treatment of chronic kidney disease (CKD) can slow its progression to end-stage renal disease (ESRD). However, the therapies remain limited. Blood pressure control using angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) has the greatest weight of evidence. Glycemic control in diabetes seems likely to retard progression. Several metabolic disturbances of CKD may prove to be useful therapeutic targets but have been insufficiently tested. These include acidosis, hyperphosphatemia, and vitamin D deficiency. Drugs aimed at other potentially damaging systems and processes, including endothelin, fibrosis, oxidation, and advanced glycation end products, are at various stages of development. In addition to the paucity of proven effective therapies, the incomplete application of existing treatments, the education of patients about their disease, and the transition to ESRD care remain major practical barriers to better outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research